Original Literature | Model OverView |
---|---|
Publication
Title
Structural and functional analyses of bacterial lipopolysaccharides.
Affiliation
Equipe Endotoxines, UMR 8619 du Centre National de la Recherche Scientifique,Biochimie, Universite de Paris-Sud, Orsay, France.martine.caroff@bbmpc.u-psud.fr
Abstract
Bacterial lipopolysaccharides (LPSs) are powerful immunomodulators in infectedhosts, and may cause endotoxic shock. Most of them share a common architecturebut vary considerably in structural motifs from one genus, species, and strainto another. Cells of the innate immune response recognize evolutionarilyconserved LPS molecular patterns of endotoxins and structural details therebygreatly influencing their response.
PMID
12106784
|
Entity
--
e1
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane
--
--
--
csml-variable:Double
m1
0
infinite
0
--
--
e10
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytosol
--
--
--
csml-variable:Double
m10
0
infinite
0
--
LPS:CD14
--
e11
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m11
0
infinite
0
--
csml-variable:Double
m12
0
infinite
0
--
csml-variable:Double
m13
0
infinite
0
--
P2X7
--
e14
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m14
0
infinite
0
--
LPS:P2X7
--
e15
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m15
0
infinite
0
--
LPS: HSP70/HSP90/CXCR4/GDF
--
e16
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m16
0
infinite
0
--
LPS: CD55
--
e17
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m17
0
infinite
0
--
CR3
--
e18
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m18
0
infinite
0
--
LPS: CR3
--
e19
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
csml-variable:Double
m19
0
infinite
0
--
--
e2
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m2
0
infinite
0
--
TLR2
--
e20
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m20
0
infinite
0
--
LPS: TLR2
--
e21
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m21
0
infinite
0
--
TLR4
--
e22
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m22
0
infinite
0
--
LPS: TLR4
--
e23
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m23
0
infinite
0
--
csml-variable:Double
m24
0
infinite
0
--
LPS: TLR4: MyD88
--
e25
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m25
0
infinite
0
--
csml-variable:Double
m26
0
infinite
0
--
csml-variable:Double
m27
0
infinite
0
--
csml-variable:Double
m28
0
infinite
0
--
csml-variable:Double
m29
0
infinite
0
--
--
e3
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
--
csml-variable:Double
m3
0
infinite
0
--
csml-variable:Double
m30
0
infinite
0
--
IKK-alpha/beta{activated}
--
e31
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m31
0
infinite
0
--
csml-variable:Double
m32
0
infinite
0
--
p65/p50{activated}
--
e33
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m33
0
infinite
0
--
TIRAP
--
e34
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m34
0
infinite
0
--
LPS: TLR4: TIRAP
--
e35
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m35
0
infinite
0
--
csml-variable:Double
m36
0
infinite
0
--
csml-variable:Double
m37
0
infinite
0
--
csml-variable:Double
m38
0
infinite
0
--
csml-variable:Double
m39
0
infinite
0
--
--
e4
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m4
0
infinite
0
--
csml-variable:Double
m40
0
infinite
0
--
p38MAPK{activated}
--
e41
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m41
0
infinite
0
--
csml-variable:Double
m42
0
infinite
0
--
csml-variable:Double
m43
0
infinite
0
--
csml-variable:Double
m44
0
infinite
0
--
csml-variable:Double
m45
0
infinite
0
--
csml-variable:Double
m46
0
infinite
0
--
csml-variable:Double
m47
0
infinite
0
--
csml-variable:Double
m48
0
infinite
0
--
csml-variable:Double
m49
0
infinite
0
--
LPS
--
e5
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
csml-variable:Double
m5
0
infinite
0
--
--
e50
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelopeLumen
--
--
--
csml-variable:Double
m50
0
infinite
0
--
--
e51
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearPore
--
--
--
csml-variable:Double
m51
0
infinite
0
--
--
e52
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearInnerMembrane
--
--
--
csml-variable:Double
m52
0
infinite
0
--
--
e53
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearLumen
--
--
--
csml-variable:Double
m53
0
infinite
0
--
--
e54
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearOuterMembrane
--
--
--
csml-variable:Double
m54
0
infinite
0
--
--
e55
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleus
--
--
--
csml-variable:Double
m55
0
infinite
0
--
--
e56
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleoplasm
--
--
--
csml-variable:Double
m56
0
infinite
0
--
--
e57
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearBody
--
--
--
csml-variable:Double
m57
0
infinite
0
--
--
e58
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleolus
--
--
--
csml-variable:Double
m58
0
infinite
0
--
--
e59
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelope
--
--
--
csml-variable:Double
m59
0
infinite
0
--
CD14
--
e6
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m6
0
infinite
0
--
--
e60
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Chromatin
--
--
--
csml-variable:Double
m60
0
infinite
0
--
--
e61
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearChromosome
--
--
--
csml-variable:Double
m61
0
infinite
0
--
--
e62
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearCentromere
--
--
--
csml-variable:Double
m62
0
infinite
0
--
csml-variable:Double
m63
0
infinite
0
--
csml-variable:Double
m64
0
infinite
0
--
p65/p50_nucleus
--
e65
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m65
0
infinite
0
--
csml-variable:Double
m66
0
infinite
0
--
pI-3 kinase{activated}
--
e67
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m67
0
infinite
0
--
csml-variable:Double
m68
0
infinite
0
--
csml-variable:Double
m69
0
infinite
0
--
--
e7
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell
--
--
--
csml-variable:Double
m7
0
infinite
0
--
csml-variable:Double
m70
0
infinite
0
--
IL-1ra
--
e71
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m71
0
infinite
0
--
csml-variable:Double
m72
0
infinite
0
--
csml-variable:Double
m73
0
infinite
0
--
csml-variable:Double
m74
0
infinite
0
--
--
e8
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell_WithoutCellWall_
--
--
--
csml-variable:Double
m8
0
infinite
0
--
--
e9
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytoplasm
--
--
--
csml-variable:Double
m9
0
infinite
0
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c1 : 1
stoichiometry:c2 : 1
stoichiometry:c3 : 1
m6*m5*0.1
nodelay
--
0
PMID: 12106784, 10706718 Epitope-mapping studies revealed that CD14 selectively recognizes E. coli, P. gingivalis and H. pylori LPSs and that hydrophilic domains of the amino-terminal region of CD14 are involved in LPS binding.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c28 : 1
stoichiometry:c30 : 1
stoichiometry:c29 : 1
m28*m27*0.1
nodelay
--
0
PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c31 : 1
stoichiometry:c33 : 1
stoichiometry:c32 : 1
m30*m29*0.1
nodelay
--
0
PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c34 : 1
stoichiometry:c36 : 1
stoichiometry:c35 : 1
m32*m31*0.1
nodelay
--
0
PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c37 : 1
stoichiometry:c38 : 1
stoichiometry:c39 : 1
m34*m23*0.1
nodelay
--
0
PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c40 : 1
stoichiometry:c46 : 1
stoichiometry:c41 : 1
m36*m35*0.1
nodelay
--
0
PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c42 : 1
stoichiometry:c47 : 1
stoichiometry:c43 : 1
m38*m37*0.1
nodelay
--
0
PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c44 : 1
stoichiometry:c48 : 1
stoichiometry:c45 : 1
m40*m39*0.1
nodelay
--
0
PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c57 : 1
stoichiometry:c52 : 1
m23*0.1
nodelay
--
0
PMID: 12106784, 9058830, 10940876 human PBMC in the presence of IL-4 and granulocyte-macrophage-CSF, produce high levels of TNF-¦Á, IL-6, IL-8, and IL-12 upon LPS stimulation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c49 : 1
stoichiometry:c55 : 1
stoichiometry:c50 : 1
m44*m41*0.1
nodelay
--
0
PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c56 : 1
stoichiometry:c51 : 1
m23*0.1
nodelay
--
0
PMID: 12106784, 9058830, 10940876 human PBMC in the presence of IL-4 and granulocyte-macrophage-CSF, produce high levels of TNF-¦Á, IL-6, IL-8, and IL-12 upon LPS stimulation.
p2
p2
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c4 : 1
stoichiometry:c5 : 1
stoichiometry:c6 : 1
m14*m5*0.1
nodelay
--
0
PMID: 12106784, 11489964 several other molecules are still good candidates as LPS receptors, i.e., complement CR3 receptor, CD55 , HSP 70 and 90 associated with CXCR4 and GDF, P2X7, etc.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c59 : 1
stoichiometry:c61 : 1
stoichiometry:c60 : 1
m48*m37*0.1
nodelay
--
0
PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c62 : 1
stoichiometry:c64 : 1
stoichiometry:c63 : 1
m40*m49*0.1
nodelay
--
0
PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c65 : 1
stoichiometry:c67 : 1
stoichiometry:c66 : 1
m63*m41*0.1
nodelay
--
0
PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c68 : 1
stoichiometry:c69 : 1
m33*0.1
nodelay
--
0
PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c70 : 1
stoichiometry:c72 : 1
stoichiometry:c71 : 1
m66*m23*0.1
nodelay
--
0
PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c73 : 1
stoichiometry:c74 : 1
stoichiometry:c75 : 1
m67*m32*0.1
nodelay
--
0
PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c76 : 1
stoichiometry:c77 : 1
m65*0.1
nodelay
--
0
PMID: 12106784 Fig.4
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c79 : 1
stoichiometry:c53 : 1
m65*0.1
nodelay
--
0
PMID: 12106784 Fig.4
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c54 : 1
stoichiometry:c78 : 1
m23*0.1
nodelay
--
0
PMID: 12106784, 9058830, 10940876 human PBMC in the presence of IL-4 and granulocyte-macrophage-CSF, produce high levels of TNF-¦Á, IL-6, IL-8, and IL-12 upon LPS stimulation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c88 : 1
stoichiometry:c84 : 1
m41*0.1
nodelay
--
0
PMID: 12106784, 11402003 Blocking of the p38 pathway before LPS stimulation decreased IL-1¦Á, IL-1ra, and TNF-¦Á production by human monocytes.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c10 : 1
stoichiometry:c11 : 1
stoichiometry:c12 : 1
m12*m5*0.1
nodelay
--
0
PMID: 12106784, 10219599 several other molecules are still good candidates as LPS receptors, i.e., complement CR3 receptor, CD55, HSP 70 and 90 associated with CXCR4 and GDF, P2X7, etc.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c82 : 1
stoichiometry:c80 : 1
m11*0.1
nodelay
--
0
PMID: 12106784, 9767415 LPS-induced IL-1 production is mediated by CD14-dependent mechanisms in the presence of plasma, whereas in its absence, both CD14-dependent and CD14-independent pathways are involved.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c83 : 1
stoichiometry:c81 : 1
m23*0.1
nodelay
--
0
PMID: 12106784, 9767415 LPS-induced IL-1 production is mediated by CD14-dependent mechanisms in the presence of plasma, whereas in its absence, both CD14-dependent and CD14-independent pathways are involved.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c87 : 1
stoichiometry:c85 : 1
m41*0.1
nodelay
--
0
PMID: 12106784, 11402003 Blocking of the p38 pathway before LPS stimulation decreased IL-1¦Á, IL-1ra, and TNF-¦Á production by human monocytes.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c89 : 1
stoichiometry:c86 : 1
m41*0.1
nodelay
--
0
PMID: 12106784, 11402003 Blocking of the p38 pathway before LPS stimulation decreased IL-1¦Á, IL-1ra, and TNF-¦Á production by human monocytes.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c93 : 1
stoichiometry:c92 : 1
m23*0.1
nodelay
--
0
PMID: 12106784, 10940876 human PBMC in the presence of IL-4 and granulocyte-macrophage-CSF, produce high levels of TNF-¦Á, IL-6, IL-8, and IL-12 upon LPS stimulation and upregulate their expression of HLA-DR, B7-1, B7-2, and CD40.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c94 : 1
stoichiometry:c91 : 1
m23*0.1
nodelay
--
0
PMID: 12106784, 10940876 human PBMC in the presence of IL-4 and granulocyte-macrophage-CSF, produce high levels of TNF-¦Á, IL-6, IL-8, and IL-12 upon LPS stimulation and upregulate their expression of HLA-DR, B7-1, B7-2, and CD40.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c95 : 1
stoichiometry:c90 : 1
m23*0.1
nodelay
--
0
PMID: 12106784, 10940876 human PBMC in the presence of IL-4 and granulocyte-macrophage-CSF, produce high levels of TNF-¦Á, IL-6, IL-8, and IL-12 upon LPS stimulation and upregulate their expression of HLA-DR, B7-1, B7-2, and CD40.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c7 : 1
stoichiometry:c8 : 1
stoichiometry:c9 : 1
m13*m5*0.1
nodelay
--
0
PMID: 12106784, 11276205 several other molecules are still good candidates as LPS receptors, i.e., complement CR3 receptor, CD55 , HSP 70 and 90 associated with CXCR4 and GDF, P2X7, etc.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c13 : 1
stoichiometry:c14 : 1
stoichiometry:c15 : 1
m18*m5*0.1
nodelay
--
0
PMID: 12106784 several other molecules are still good candidates as LPS receptors, i.e., complement CR3 receptor, CD55, HSP 70 and 90 associated with CXCR4 and GDF, P2X7, etc.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c16 : 1
stoichiometry:c17 : 1
stoichiometry:c18 : 1
m11*m20*0.1
nodelay
--
0
PMID: 12106784 Genetic approaches have involved TLR2 and TLR4 in LPS recognition.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c19 : 1
stoichiometry:c20 : 1
stoichiometry:c21 : 1
stoichiometry:c58 : 1
m11*m22*0.1
nodelay
--
0
PMID: 12106784 Genetic approaches have involved TLR2 and TLR4 in LPS recognition.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c22 : 1
stoichiometry:c23 : 1
stoichiometry:c24 : 1
m23*m24*0.1
nodelay
--
0
PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c25 : 1
stoichiometry:c26 : 1
stoichiometry:c27 : 1
m25*m26*0.1
nodelay
--
0
PMID: 12106784 TLRs are structurally characterized by a cytoplasmic Toll/interleukin-1R (TIR) domain and an extracellular leucine-rich domain activating the MyD88/IRAK signaling cascade, which leads to NF-kB and c-Jun/ATF2/TCF activation.
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--